⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22811945 | 0.85 | — | — | |
| SCHEMBL3626663 | 0.80 | — | — | |
| SCHEMBL24290438 | 0.75 | — | — | |
| SCHEMBL27460224 | 0.74 | — | — | |
| SCHEMBL1307154 | 0.74 | — | — | |
| SCHEMBL24982141 | 0.74 | KCNH2 (0.33) | — | |
| SCHEMBL6072132 | 0.74 | — | — | |
| SCHEMBL4719480 | 0.74 | — | — | |
| SCHEMBL1485934 | 0.72 | — | — | |
| Hydrochloric Acid SCHEMBL28291319 | 0.72 | ADH1B (0.62) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230313195-A1 | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE | Suzhou Ribo Life Science Co., Ltd. (CN) | 2023-10-05 | — | — | US | disclosed |
| US-20230181742-A1 | AMINE-CONTAINING TRANSFECTION REAGENTS AND METHODS FOR MAKING AND USING SAME | Life Technologies Corporation | 2023-06-15 | — | — | US | disclosed |
| US-20230132756-A1 | DOUBLE-STRANDED OLIGONUCLEOTIDE, COMPOSITION AND CONJUGATE COMPRISING DOUBLE-STRANDED OLIGONUCLEOTIDE, PREPARATION METHOD THEREOF AND USE THEREOF | Suzhou Ribo Life Science Co., Ltd. (CN) | 2023-05-04 | — | — | US | disclosed |
| WO-2022073469-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI) , INC. (CN) | 2022-04-14 | — | — | WO | disclosed |
| WO-2021154665-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-08-05 | — | — | WO | disclosed |
| EP-3799872-A1 | TETRAHYDROQUINOLINE DERIVATIVES FOR USE AS BET INHIBITORS | Forma Therapeutics, Inc. (US) | 2021-04-07 | — | — | EP | disclosed |
| EP-3698796-A1 | PHARMACEUTICAL COMBINATION OF A TRICYCLIC BETA-LACTAMASE INHIBITOR WITH SPECIFIC BETA-LACTAM ANTIBIOTICS | Novartis AG (CH) | 2020-08-26 | — | — | EP | disclosed |
| US-20180200374-A1 | AMINE-CONTAINING TRANSFECTION REAGENTS AND METHODS FOR MAKING AND USING SAME | Life Technologies Corporation | 2018-07-19 | — | — | US | disclosed |
| US-9901642-B2 | Amine-containing transfection reagents and methods for making and using same | Life Technologies Corporation (US) | 2018-02-27 | — | — | US | disclosed |
| US-20150174260-A1 | AMINE-CONTAINING TRANSFECTION REAGENTS AND METHODS FOR MAKING AND USING SAME | Life Technologies Corporation | 2015-06-25 | — | — | US | disclosed |
| US-20120136073-A1 | Amine-Containing Transfection Reagents and methods for making and using same | Life Technologies Corporation (US) | 2012-05-31 | — | — | US | disclosed |